Investors must take note of Adma Biologics Inc’s (ADMA) performance last week, which was -0.98%.

A new trading day began on Monday, with Adma Biologics Inc (NASDAQ: ADMA) stock price up 0.61% from the previous day of tradingbefore settling in for the closing price of $18.09. ADMA’s price has ranged from $3.06 to $19.34 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 73.26%. Meanwhile, its annual earnings per share averaged 471.15%. With a float of $225.18 million, this company’s outstanding shares have now reached $226.06 million.

The extent of productivity of a business whose workforce counts for 624 workers is very important to gauge. In terms of profitability, gross margin is 45.96%, operating margin of 25.42%, and the pretax margin is 11.86%.

Adma Biologics Inc (ADMA) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.39%, while institutional ownership is 77.86%. The most recent insider transaction that took place on Sep 09 ’24, was worth 166,189. In this transaction Director of this company sold 9,000 shares at a rate of $18.47, taking the stock ownership to the 153,941 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Director proposed sale 9,000 for $16.26, making the entire transaction worth $146,340.

Adma Biologics Inc (ADMA) Latest Financial update

In its latest quarterly report, released on 6/30/2024, the company reported earnings of 0.01 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 471.15% per share during the next fiscal year.

Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators

Here are Adma Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.85. Likewise, its price to free cash flow for the trailing twelve months is 63.66.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit 0.13 in the next quarter and is forecasted to reach 0.66 in one year’s time.

Technical Analysis of Adma Biologics Inc (ADMA)

The latest stats from [Adma Biologics Inc, ADMA] show that its last 5-days average volume of 5.51 million was superior to 3.15 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.54%. Additionally, its Average True Range was 0.95.

During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 91.28%, which indicates a significant increase from 65.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.86% in the past 14 days, which was lower than the 69.97% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $15.08, while its 200-day Moving Average is $8.75. Now, the first resistance to watch is $18.70. This is followed by the second major resistance level at $19.20. The third major resistance level sits at $19.70. If the price goes on to break the first support level at $17.70, it is likely to go to the next support level at $17.20. The third support level lies at $16.70 if the price breaches the second support level.

Adma Biologics Inc (NASDAQ: ADMA) Key Stats

With a market capitalization of 4.24 billion, the company has a total of 231,809K Shares Outstanding. Currently, annual sales are 258,220 K while annual income is -28,240 K. The company’s previous quarter sales were 107,190 K while its latest quarter income was 32,060 K.